Guideline Recommendations for Migraine with Brainstem Aura

Clinical Presentation

Dysarthria (slurred speech) is a recognized brain‑stem aura symptom in migraine with brainstem aura. 1
Aura symptoms typically develop gradually over ≥ 5 minutes, last 5–60 minutes, and are followed by headache within 60 minutes. 2, 1

Complex partial seizures (temporal‑lobe epilepsy) must be excluded when evaluating patients with suspected migraine with brainstem aura. 1

Non‑steroidal anti‑inflammatory drugs (e.g., ibuprofen 400–800 mg, naproxen 500–825 mg) are the safest first‑line acute therapy for migraine with brainstem aura. 2, 3
Antiemetics such as metoclopramide 10 mg or prochlorperazine 10 mg provide synergistic analgesia and treat nausea during acute attacks. 2
Opioids and butalbital‑containing compounds should be avoided because of limited efficacy, dependence risk, and propensity to cause medication‑overuse headache. 2
Acute migraine medications should be limited to ≤ 2 days per week (≤ 10 days per month) to prevent medication‑overuse headache. 2, 1

Preventive therapy is indicated when attacks occur ≥ 2 times per month causing disability ≥ 3 days, or when acute medication use exceeds twice weekly. 2
Propranolol (80–240 mg/day) is a first‑line preventive agent for migraine with brainstem aura. 2
Topiramate (titrated to effect, typically 50–200 mg/day) is a first‑line preventive agent. 2
Amitriptyline (30–150 mg/day) is a second‑line preventive option, especially useful when comorbid depression or sleep disturbance is present. 2
Sodium valproate (800–1500 mg/day) is effective but is absolutely contraindicated in women of childbearing potential because of teratogenic risk. 2

Bed rest alone may be sufficient for short‑duration attacks in adolescents and young adults. 2
In women of childbearing potential, acetaminophen 1000 mg is recommended for acute treatment when pregnancy is possible or confirmed. 2

Maintaining a headache diary is essential for tracking attack frequency, severity, and medication use. 2
Referral to a headache specialist is indicated when the diagnosis is uncertain, all treatments fail, or complications arise. 2

Prescribing triptans for migraine with brainstem aura remains contraindicated per FDA labeling; avoidance is advised until formal revision. (no citation, omitted)
Exceeding the recommended ≤ 2 days/week limit for acute medications creates medication‑overuse headache and can convert episodic migraine to chronic migraine. 2
Valproate must not be prescribed to women of childbearing age due to unacceptable teratogenic risk. 2

Onset of apparent migraine after the age of 50 years should arouse suspicion of an underlying cause, as migraine often remits with older age while the incidence of secondary headaches increases 4, 5, 6
Late-onset migraine (after age 40) requires thorough investigation as it deviates from typical age patterns 6
When migraine-like symptoms first appear in middle age, secondary headache disorders must be excluded 4, 5
For definitive diagnosis of migraine without aura, at least 5 attacks fulfilling ICHD-3 criteria are required 7
For migraine with aura, at least 2 attacks with specific aura characteristics are needed 7

First-line acute treatment includes NSAIDs with antiemetics as needed 4, 5
If three consecutive attacks don't respond to NSAIDs, triptans should be considered 4, 5
In older patients with migraine, monitor blood pressure regularly if triptans are prescribed due to potential cardiovascular concerns 4, 5
Consider preventive treatment if migraine adversely affects the patient on ≥2 days per month despite optimized acute treatment 6

Beta-blockers (atenolol, bisoprolol, metoprolol, propranolol) are first-line preventive options 5, 6
Topiramate is a first-line preventive option 5, 6
Candesartan is a first-line preventive option 5, 6, 8
Flunarizine is a second-line preventive option 5, 6
Amitriptyline is a second-line preventive option 5, 6, 8
Sodium valproate (specifically recommended for men) is a second-line preventive option 4, 5, 6

Failure to investigate for secondary causes in late-onset migraine presentations should be avoided 4, 5, 6
Overlooking cardiovascular risk factors when prescribing triptans to older patients should be avoided 4, 5
Neglecting to monitor for medication overuse headache with frequent use of acute medications should be avoided 8
Missing potential comorbidities that may influence treatment selection should be avoided 8